Volume IV · Issue 21 · June 2026
An evidence-
first reference
for peptide
therapeutics.
Plain-language profiles for 82 peptides — graded for evidence and risk, sourced from primary literature. For educational purposes only.
- NewRetatrutide Phase II reanalysisPEP-0084
- RevisedBPC-157 risk bandPEP-0014
- UpdatedSemaglutide adverse-event registryPEP-0001
- NoteMethodology v0.4 publishedMETH
How we grade what we publish
Evidence Scale
- StrongStrong human RCT or meta-analysis
- ModerateMultiple human trials, mixed outcomes
- LimitedSmall or single human study
- PreliminaryAnimal or in-vitro only
Risk Bands
- LowWell-characterized, minor reported AEs
- ModerateKnown AEs, monitoring advised
- ElevatedSerious AEs reported or theoretical
- HighWithdrawn, banned, or major safety signals
Browse by research goal
Tissue recovery
Soft-tissue, tendon, gut healing
Metabolic health
Glycemic control, body composition
Longevity & repair
Senescence, mitochondrial, cellular
Cognition & mood
Focus, neuroprotection, anxiolysis
Sleep & circadian
Sleep architecture, GH-axis at night
Lean mass
GH-axis, anabolic signalling
Skin & hair
Dermal repair, pigment, follicle support
Immune modulation
Thymic activity, viral context
Featured profiles
SEMAGLUTIDE
Long-acting GLP-1 receptor agonist with extensive Phase III and post-marketing data for type-2 diabetes and obesity.
TIRZEPATIDE
TIRZEPATIDE is catalogued in the Peptides Pub research index, with coverage focused on Metabolic health, Cognition & mood.
Retatrutide
Triple GIP/GLP-1/glucagon receptor agonist. Phase II data shows substantial weight reduction. Under investigation for metabolic disease.
GHK-Cu
Copper-binding tripeptide present in human plasma; extensive cosmetic literature, limited systemic data.
Start with three questions, end with a shortlist.
Pick a goal, a risk posture, and an evidence floor. We return a narrow list of peptides worth understanding — not a prescription.
Open guided startOpen the encyclopedia and filter.
Search by name or filter by evidence strength, risk band, regulatory status, and indication.
Open encyclopedia